Preclinical data support 4M Therapeutics’ GSK-3β inhibitors for treatment of bipolar disorder and acute mania

May 14, 2024

4M Therapeutics Inc. has announced the presentation of preclinical data on its small-molecule glycogen synthase kinase-3β (GSK-3β) inhibitors in models of bipolar disorder.

BioWorld Asia BioWorld Science Neurology/psychiatric

Today's news in brief

BioWorld

BioWorld briefs for Nov. 8, 2024.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for November 8, 2024.

Gray and green glass dollar symbols with arrow pointing up

Sales balloon for GLP-1 drugs from Novo Nordisk, Eli Lilly

BioWorld

Nearly $3.8 billion was earned by Novo Nordisk A/S and Eli Lilly and Co. in the third quarter for their glucagon-like peptide-1 (GLP-1) drugs to treat obesity....

Regulatory actions for Oct. 31, 2024

BioWorld

Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Capsida, Electra,...

Australia reimburses Vazkepa a decade after US approval

BioWorld

For the first time, Australians have access to CSL Inc.’s Vazkepa (icosapent ethyl/Vascepa) for managing cardiovascular disease more than a decade after the drug...